Getting Zemaira
What can I expect after my doctor prescribes Zemaira?
When you first start therapy, it's natural to feel overwhelmed by the process. Here
is what you can expect:
- Your doctor will send a referral to a specialty pharmacy. The two
specialty pharmacies that your doctor may use are Accredo and Coram (a division
of Apria Healthcare).
- An advocate from the specialty pharmacy might contact you to obtain more information
about your healthcare coverage or to explain further aspects of your care.
-
A case manager from AccessMed – a third-party administrator that works with
CSL Behring – will make initial contact with you. Your case manager will assist
you with anything you need as you begin therapy, such as helping you develop coping
strategies or suggesting an activity program.
At this time, you'll also have the opportunity to get in touch with a
mentor who can help guide you. Additionally, if you've already had contact
with a Patient Support Specialist as part of your decision-making process, or would
like to begin speaking with one, you can also opt-in for contact with them.
Remember, you can decline the services of CareZ at any time. We know this can be
a trying time for you, and we want to be there to help make it easier.
For additional assistance and answers from a friendly and knowledgeable representative, contact CareZ at 1-888-415-2167.
Zemaira Product Samples
We are pleased to provide patients with Alpha-1–associated emphysema the option of trying Zemaira for up to 2 weeks.*
If you are interested in this opportunity, please take the following steps to see
if you qualify:
- Talk with your doctor to determine how and where you might receive infusions of
Zemaira
- Your doctor may need your help filling out any necessary forms for you to continue
taking Zemaira after the end of your trial period
If you have any questions or would like more information, please call
1-866-ZEMAIRA (1-866-936-2472).
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.